Earnings Scheduled For November 24, 2021
Companies Reporting Before The Bell
• Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million.
Earnings Outlook For Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.
Analysts estimate that Anavex Life Sciences will likely report an Earnings Per Share (EPS) of $-0.15.
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting season and ahead of the holiday week.
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX 2-73 in Patients with Alzheimer’s Disease
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and
BTIG Initiates Coverage On Anavex Life Sciences with Buy Rating, Announces Price Target of $35
BTIG analyst Yun Zhong initiates coverage on Anavex Life Sciences (NASDAQ:AVXL) with a Buy rating and announces Price Target of $35.
Anavex Life Sciences Granted U.S. Patent Titled ‘Anavex2-73 for the treatment of alzheimer’s disease’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6666&f=G&l=50&d=PTXT&p=134&S1=20210831&OS=20210831&RS=20210831
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX 2-73 in Fragile X Syndrome
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and